Filing Details
- Accession Number:
- 0001179110-13-007709
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-05-03 17:35:27
- Reporting Period:
- 2013-05-01
- Filing Date:
- 2013-05-03
- Accepted Time:
- 2013-05-03 17:35:27
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1436304 | Kythera Biopharmaceuticals Inc | KYTH | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1559531 | E Nathaniel David | C/O Kythera Biopharmaceuticals, Inc. 27200 West Agoura Road, Suite 200 Calabasas CA 91301 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2013-05-01 | 2,362 | $23.33 | 547,024 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2013-05-01 | 200 | $24.03 | 546,824 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan which expires April 9, 2014.
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.71, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.815 to $24.45, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Billionaire Hedge Funds
